About SYNAPS Dx
SYNAPS Dx is a company based in Rockville (United States) founded in 2016.. SYNAPS Dx has raised $10 million across 2 funding rounds from investors including Semler Scientific. SYNAPS Dx offers products and services including DISCERN™ Test. SYNAPS Dx operates in a competitive market with competitors including Todos Medical, C₂N Diagnostics, ADmit Therapeutics, ALZpath and Amydis Diagnostics, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neurodiagnostics Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SYNAPS Dx
SYNAPS Dx offers a comprehensive portfolio of products and services, including DISCERN™ Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Skin sample test for identifying and distinguishing Alzheimer's disease.
Unlock access to complete
Unlock access to complete
Funding Insights of SYNAPS Dx
SYNAPS Dx has successfully raised a total of $10M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(12 Oct 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2022 | Amount | Series A - SYNAPS Dx | Valuation |
investors |
|
| Oct, 2021 | Amount | Series A - SYNAPS Dx | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SYNAPS Dx
SYNAPS Dx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Semler Scientific. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Point-of-care devices for peripheral arterial disease screening are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SYNAPS Dx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SYNAPS Dx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Synaps Dx Comparisons
Competitors of SYNAPS Dx
SYNAPS Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Todos Medical, C₂N Diagnostics, ADmit Therapeutics, ALZpath and Amydis Diagnostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Todos Medical is focused on developing diagnostic blood tests.
|
|
| domain | founded_year | HQ Location |
Diagnostics and therapies for Alzheimer's disease are developed.
|
|
| domain | founded_year | HQ Location |
Early Alzheimer's detection is facilitated through blood-based epigenetic diagnostics.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions for Alzheimer's disease are developed using blood-based biomarkers.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostics test for detection of Alzheimer's disease
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Synaps Dx
Frequently Asked Questions about SYNAPS Dx
When was SYNAPS Dx founded?
SYNAPS Dx was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Where is SYNAPS Dx located?
SYNAPS Dx is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of SYNAPS Dx?
Frank Amato is the current CEO of SYNAPS Dx.
Is SYNAPS Dx a funded company?
SYNAPS Dx is a funded company, having raised a total of $10M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Oct 12, 2021.
What does SYNAPS Dx do?
SYNAPS Dx was founded in 2016 and is headquartered in Rockville, United States, within the biotechnology sector focused on neurological diagnostics. A test called DISCERN is provided for the definitive diagnosis of Alzheimers disease through minimally invasive skin samples. Detection of dementia is achieved by analyzing three specific biomarkers. Operations center on advancing non-invasive methods for early identification in clinical settings.
Who are the top competitors of SYNAPS Dx?
SYNAPS Dx's top competitors include ADmit Therapeutics, C₂N Diagnostics and Todos Medical.
What products or services does SYNAPS Dx offer?
SYNAPS Dx offers DISCERN™ Test.
Who are SYNAPS Dx's investors?
SYNAPS Dx has 1 investor. Key investors include Semler Scientific.